Moore Capital Management LP Has $4.10 Million Stock Position in Baxter International Inc. $BAX

Moore Capital Management LP trimmed its stake in shares of Baxter International Inc. (NYSE:BAX) by 45.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,227 shares of the medical instruments supplier’s stock after selling 162,329 shares during the quarter. Moore Capital Management LP’s holdings in Baxter International were worth $4,098,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Baird Financial Group Inc. raised its stake in Baxter International by 3.2% during the second quarter. Baird Financial Group Inc. now owns 52,436 shares of the medical instruments supplier’s stock worth $1,588,000 after buying an additional 1,604 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Baxter International by 2.9% during the second quarter. California State Teachers Retirement System now owns 649,463 shares of the medical instruments supplier’s stock worth $19,666,000 after purchasing an additional 18,439 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Baxter International by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock valued at $231,304,000 after purchasing an additional 97,687 shares during the period. BI Asset Management Fondsmaeglerselskab A S increased its stake in shares of Baxter International by 21.4% during the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 24,356 shares of the medical instruments supplier’s stock worth $737,000 after purchasing an additional 4,293 shares during the last quarter. Finally, Captrust Financial Advisors increased its holdings in Baxter International by 5.5% in the 2nd quarter. Captrust Financial Advisors now owns 53,933 shares of the medical instruments supplier’s stock worth $1,633,000 after acquiring an additional 2,813 shares during the last quarter. 90.19% of the stock is currently owned by institutional investors and hedge funds.

Baxter International Stock Performance

Shares of BAX opened at $26.08 on Tuesday. The company has a 50-day simple moving average of $24.37 and a two-hundred day simple moving average of $20.57. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market capitalization of $13.48 billion, a PE ratio of -12.60, a price-to-earnings-growth ratio of 3.96 and a beta of 0.59. Baxter International Inc. has a one year low of $15.73 and a one year high of $30.00.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $2.80 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. On average, analysts anticipate that Baxter International Inc. will post 2.04 EPS for the current fiscal year.

Baxter International Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Friday, August 28th will be paid a dividend of $0.01 per share. The ex-dividend date of this dividend is Friday, August 28th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s dividend payout ratio (DPR) is currently -1.93%.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on BAX. Wells Fargo & Company upped their price target on Baxter International from $19.00 to $23.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. The Goldman Sachs Group raised their price objective on Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Weiss Ratings upgraded shares of Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. TD Cowen raised their target price on Baxter International from $20.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, July 27th. Finally, UBS Group boosted their price target on Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a report on Tuesday, July 28th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Baxter International currently has a consensus rating of “Hold” and a consensus price target of $22.45.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.